Observational Study for Subjects With Pompe Disease Undergoing Immune Modulation Therapies

NCT01451879 · clinicaltrials.gov ↗

COMPLETED

Status

11

Enrollment

OTHER

Sponsor class

Conditions

Pompe Disease

Interventions

DRUG: Rituximab
DRUG: Miglustat

Sponsor

University of Florida